Madopar Lt

Levodopa/Benserazide, the active ingredients in Madopar LT, are a dopamine precursor and a dopa decarboxylase inhibitor presented as an extended‑release tablet for oral use. They treat Parkinson's disease and idiopathic Parkinsonian syndrome by increasing central dopamine availability. The combination works synergistically so that more levodopa bypasses peripheral metabolism and reaches the brain, where it is converted into dopamine to improve motor function.

GNH USA supplies Madopar LT as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Madopar LT is used in the management of Parkinsonian disorders, targeting motor symptoms associated with dopamine deficiency. - Parkinson's disease: improves motor control and reduces rigidity, tremor, and bradykinesia. - Idiopathic Parkinsonian syndrome: alleviates symptoms by restoring central dopamine levels.

Madopar LT may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Vomiting - Dizziness or light‑headedness - Orthostatic hypotension - Dry mouth - Constipation

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or psychosis - Severe hypotension or syncope - Neuroleptic malignant syndrome (rare) - Severe allergic reactions (rash, angioedema) - Serotonin syndrome when combined with serotonergic agents

When prescribing Madopar LT, clinicians should consider several safety measures to minimize risks. - Monitor motor fluctuations: adjust dose based on symptom control. - Assess cardiovascular status: watch for orthostatic hypotension and arrhythmias. - Evaluate psychiatric symptoms: be alert to hallucinations or confusion. - Avoid abrupt discontinuation: taper gradually to prevent withdrawal effects. - Use with caution in hepatic or renal impairment: dose may need adjustment. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Madopar LT can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis. - Antipsychotics that block dopamine receptors (e.g., haloperidol): reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - COMT inhibitors (e.g., entacapone): increase levodopa plasma levels. - SSRIs or SNRIs: potential for serotonin syndrome. - Iron or calcium supplements: may decrease levodopa absorption if taken together.